Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097985 | 1.00 | KDM4D (0.46) | KDM4DKMT2AL3MBTL1DRD2GPR119 | |
| SCHEMBL2612632 | 0.81 | KMT2A (0.45) | KDM4DKMT2AL3MBTL1DRD2KDM1A | |
| SCHEMBL20512703 | 0.81 | KDM1A (0.55) | KDM4DKMT2AL3MBTL1DRD2GPR119 | |
| SCHEMBL20512705 | 0.81 | KDM1A (0.55) | KDM4DKMT2AL3MBTL1DRD2GPR119 | |
| SCHEMBL2096601 | 0.80 | KMT2A (0.66) | KDM4DKMT2AL3MBTL1DRD2KCNA3 | |
| SCHEMBL2096599 | 0.80 | KMT2A (0.66) | KDM4DKMT2AL3MBTL1DRD2KCNA3 | |
| SCHEMBL20512881 | 0.80 | KDM1A (0.69) | KDM1A | |
| SCHEMBL20512880 | 0.80 | KDM1A (0.69) | KDM1A | |
| SCHEMBL2098129 | 0.78 | KDM1A (0.42) | KMT2AGPR119KDM1AGRM5 | |
| SCHEMBL2098131 | 0.78 | KDM1A (0.42) | KMT2AGPR119KDM1AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | KDM4D 2195/4885KMT2A 2538/4885L3MBTL1 2364/4885 |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | HSD11B1, HSD11B2, HSD3B1 | KDM4D 2463/4885KMT2A 1907/4885L3MBTL1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.